IL321437A - Bispecific antibody fusion molecules and methods of use thereof - Google Patents

Bispecific antibody fusion molecules and methods of use thereof

Info

Publication number
IL321437A
IL321437A IL321437A IL32143725A IL321437A IL 321437 A IL321437 A IL 321437A IL 321437 A IL321437 A IL 321437A IL 32143725 A IL32143725 A IL 32143725A IL 321437 A IL321437 A IL 321437A
Authority
IL
Israel
Prior art keywords
methods
bispecific antibody
antibody fusion
fusion molecules
molecules
Prior art date
Application number
IL321437A
Other languages
Hebrew (he)
Original Assignee
Evolveimmune Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evolveimmune Therapeutics Inc filed Critical Evolveimmune Therapeutics Inc
Publication of IL321437A publication Critical patent/IL321437A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
IL321437A 2022-12-14 2023-12-14 Bispecific antibody fusion molecules and methods of use thereof IL321437A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263432665P 2022-12-14 2022-12-14
PCT/US2023/084129 WO2024130032A1 (en) 2022-12-14 2023-12-14 Bispecific antibody fusion molecules and methods of use thereof

Publications (1)

Publication Number Publication Date
IL321437A true IL321437A (en) 2025-08-01

Family

ID=89983446

Family Applications (1)

Application Number Title Priority Date Filing Date
IL321437A IL321437A (en) 2022-12-14 2023-12-14 Bispecific antibody fusion molecules and methods of use thereof

Country Status (5)

Country Link
EP (1) EP4634228A1 (en)
AU (1) AU2023398887A1 (en)
CA (1) CA3277013A1 (en)
IL (1) IL321437A (en)
WO (1) WO2024130032A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3174901B1 (en) * 2014-07-31 2019-06-26 Amgen Research (Munich) GmbH Optimized cross-species specific bispecific single chain antibody constructs
WO2016105450A2 (en) * 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
US10544220B2 (en) * 2015-01-08 2020-01-28 Genmab A/S Bispecific antibodies against CD3 and CD20
IL319047A (en) * 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide assembly and methods of making and using the same
CN108290958B (en) * 2015-10-02 2021-12-28 豪夫迈·罗氏有限公司 Multispecific antibodies
WO2023178357A1 (en) * 2022-03-18 2023-09-21 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules and methods of use thereof

Also Published As

Publication number Publication date
EP4634228A1 (en) 2025-10-22
WO2024130032A1 (en) 2024-06-20
CA3277013A1 (en) 2024-06-20
AU2023398887A1 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
IL315714A (en) Bispecific antibody fusion molecules and methods of use thereof
IL317655A (en) Fcrn/antigen-binding molecules and methods of use
EP4291578A4 (en) ANTI-CD3 ANTIBODIES AND METHODS OF USE THEREOF
IL316368A (en) Anti-tl1a antibodies and methods of use thereof
IL305827A (en) Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
SI4200018T1 (en) Anti-par-2 antibodies and methods of use thereof
IL315845A (en) Anti-dectin-1 antibodies and methods of use thereof
EP4467571A4 (en) BISPECIFIC ANTI-CD3 AND ANTI-CD20 ANTIBODIES AND USE OF THEM
IL317690A (en) Anti-gpnmb antibodies and methods of use thereof
IL318694A (en) Anti-ccr8 antibodies and methods of use
EP4457248A4 (en) Single-domain high affinity antibodies and methods of use thereof
IL321437A (en) Bispecific antibody fusion molecules and methods of use thereof
HK40131724A (en) Bispecific antibody fusion molecules and methods of use thereof
HK40120973A (en) Bispecific antibody fusion molecules and methods of use thereof
IL326815A (en) Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
IL325840A (en) Bispecific pd-l1xcd28 antibodies and methods of use thereof
IL325837A (en) Bispecific pd-l1x4-1bb antibodies and methods of use thereof
IL310861A (en) Bispecific anti-flt3/cd3 antibodies and methods of use
EP4274891A4 (en) SIALIDASE-PD-1 ANTIBODY FUSION PROTEINS AND METHODS OF USE THEREOF
CA3297963A1 (en) Bispecific pd-l1x4-1bb antibodies and methods of use thereof
CA3297983A1 (en) Bispecific pd-l1xcd28 antibodies and methods of use thereof
HK40110029A (en) Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
CA3305308A1 (en) Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
CA3304207A1 (en) Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
IL318129A (en) Multivalent and bispecific antibody constructs and methods of use thereof